GlassScriptPhysician profile
Billie Xia
NPI 1497997381
$1,262.15
in general payments reported to CMS, 2019-2025
19 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $309 · 2024: $760 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $264.11 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $126.67 | 2023-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $122.45 | 2023-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $111.83 | 2023-2024 | Verquvo, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $101.41 | 2023-2024 | Xarelto |
| Exact Sciences Corporation | $70.73 | 2024-2025 | Cologuard Collection Kit |
| Scpharmaceuticals INC. | $64.62 | 2024 | |
| Glaxosmithkline, LLC. | $42.44 | 2024-2025 | Trelegy Ellipta |
| Amgen INC. | $41.64 | 2023-2024 | Repatha |
| Sumitomo Pharma America, INC. | $41.59 | 2024 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $41.06 | 2023 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.63 | 2023-2024 | Ofev |
| Eisai INC. | $36.82 | 2024-2025 | |
| Pfizer INC. | $34.32 | 2023-2024 | |
| Novo Nordisk INC | $30.62 | 2024 | Wegovy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $30.26 | 2023 | Evkeeza |
| Sanofi Pasteur INC. | $23.44 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.78 | 2023 | |
| Esperion Therapeutics, INC. | $14.73 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billie Xia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.